Products
Rezetamig Biosimilar Bispecific Antibody (CD3 × CD22) for Research
Cat No.: GMP-Bios-INN-1367
Anti-CD3 therapeutic antibody (Pre-made Rezetamig biosimilar,Bispecific (half G4-kappa_G4(VH-h-CH2-CH3))) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rezetamig (development code JNJ-75348780) is a bispecific antibody targeting CD3 and CD22. It is developed by TeneoBio and Janssen Biotech for Non-Hodgkin's lymphoma, Chronic lymphocytic leukaemia in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1367-1mg | 1mg | |
| GMP-Bios-INN-1367-10mg | 10mg | |
| GMP-Bios-INN-1367-100mg | 100mg | |
| GMP-Bios-INN-1367-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rezetamig biosimilar, Bispecific (half G4-kappa_G4(VH-h-CH2-CH3)), Anti-CD3;SIGLEC2/CD22 Antibody: Anti-CD3/CD3E/CD3e/T-cell surface glycoprotein CD3 epsilon chain therapeutic antibody |
| INN Name | Rezetamig |
| Target | CD3;SIGLEC2/CD22 |
| Format | Bispecific (half G4-kappa_G4(VH-h-CH2-CH3)) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4;G4 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | TeneoBio;Janssen Biotech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Non-Hodgkin's lymphoma;Chronic lymphocytic leukaemia |
| Production | na |
| Development Tech | na |
